Skip to main content
  • Advertise
    Want to Advertise with Us?
    Conquer welcomes advertising and sponsorship collaborations with reputable companies offering high-quality products and services to people affected by cancer.
  • Affiliated Brands
    Academy of Oncology Nurse & Patient Navigators
    The Academy of Oncology Nurse & Patient Navigators (AONN+) is the largest national specialty organization dedicated to improving patient care and quality of life by defining, enhancing, and promoting the role of oncology nurse and patient navigators. Our organization of over 8,900 members was founded in May 2009 to provide a network for all professionals involved and interested in patient navigation and survivorship care services to better manage the complexities of the cancer care treatment continuum for their patients. We view our organization as one consisting of “professional patient advocates” and, to that end, we support and serve our members.
    Journal of Oncology Navigation & Survivorship
    The Journal of Oncology Navigation & Survivorship (JONS) promotes reliance on evidence-based practices in navigating patients with cancer and their caregivers through diagnosis, treatment, and survivorship. JONS also seeks to strengthen the role of nurse and patient navigators in cancer care by serving as a platform for these professionals to disseminate original research findings, exchange best practices, and find support for their growing community.
    The Oncology Nurse-APN/PA
    The Oncology Nurse-APN/PA (TON) provides coverage of the wide spectrum of oncology-related events, trends, news, therapeutics, diagnostics, organizations, and legislation that directly affect hematology/oncology nurses and advanced practitioners involved in healthcare delivery and product utilization. The scope and coverage include a unique presentation of news and events that are shaping the care of patients with cancer.
  • Healthcare Providers
  • Contribute

Imjudo plus Imfinzi and Chemotherapy FDA Approved for Patients with Metastatic Lung Cancer

December 2022 Vol 8 No 6

In November 2022, 2 weeks after the initial approval of Imjudo (tremelimumab; from AstraZeneca), a CTLA-4 inhibitor, the FDA approved this new immunotherapy, again in combination with another immunotherapy, Imfinzi (durvalumab; from AstraZeneca), a PD-L1 inhibitor, plus platinum-based chemotherapy for the treatment of adults with metastatic (spreading) non–small-cell lung cancer (or NSCLC) that does not have EGFR or ALK genomic aberrations.

Melissa Johnson, MD

“The approval of this dual immunotherapy regimen with chemotherapy introduces a new, generally well-tolerated treatment option for patients with this devastating disease and gives them the chance to benefit from the long-term survival advantage seen with CTLA-4 inhibition,” said Melissa Johnson, MD, Director of Lung Cancer Research, Sarah Cannon Research Institute, Tennessee Oncology, Nashville.

The FDA approval was based on the results of the phase 3 clinical trial in 675 patients with metastatic NSCLC who received either the immunotherapy combination plus chemotherapy or chemotherapy alone.

The overall survival was significantly longer with the 2 immunotherapies plus chemotherapy compared with chemotherapy alone. The average survival was 14 months with the dual immunotherapy plus chemotherapy versus 11.7 months with chemotherapy alone.

The average time without disease progression was 6.2 months with the combination versus 4.8 months with chemotherapy alone. Overall, 39% of patients responded to treatment with the 2 immunotherapies plus chemotherapy versus 4% of patients who responded to chemotherapy alone. The average duration of response was 9.5 months with the combination versus 5.1 months with chemotherapy alone.

The most common side effects were nausea, fatigue, decreased appetite, musculoskeletal pain, rash, and diarrhea. Serious laboratory abnormalities were neutropenia, anemia, leukopenia, lymphocytopenia, increased lipase, hyponatremia, and thrombocytopenia.

Recommended For You